Tellgen

Tellgen Shareholder Yield

The Shareholder Yield of Tellgen (300642.SZ) as of Oct 27, 2026 is 0.97 %. In the previous year, Shareholder Yield was 1.28 % — a change of -24.49% (lower).

Shareholder Yield

0.97 %

YoY

-24.49%

Last updated:

Shareholder Yield of Tellgen is 2025 0.97 % . Shareholder Yield of Tellgen was 2024 1.28 % . It decreases by -24.49% lower compared to the previous year.

The Tellgen Shareholder Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shareholder Yield
Date
Shareholder Yield
Jan 1, 2018
0.82 CNY
Jan 1, 2019
0.94 CNY
Jan 1, 2020
1.35 CNY
Jan 1, 2021
1.24 CNY
Jan 1, 2022
1.96 CNY
Jan 1, 2023
1.23 CNY
Jan 1, 2024
1.28 CNY
Jan 1, 2025
0.97 CNY
The Tellgen Shareholder Yield history
YEARShareholder YieldYoY
0.97 %-24.49%
1.28 %+4.53%
1.23 %-37.38%
1.96 %+58.23%
1.24 %-8.19%
1.35 %+42.88%
0.94 %+15.56%
0.82 %+35.11%
0.61 %+253.25%
0.17 %+13.23%
0.15 %+362.01%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Shareholder Yield of Tellgen is 0.97 % in 2025.

Shareholder Yield of Tellgen changed from 1.28 % to 0.97 %, representing a -24.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Shareholder Yield Tellgen since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's Tellgen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tellgen

All Key Metrics — Tellgen